BioArctic Partners With Eli Lilly Over Potential New Treatment To Combine BrainTransporter Technology with Lilly's Undisclosed Drug Candidate In Neurodegeneration; BioArctic Eligible To Receive $30M Upfront Payment

Loading news article.

BioArctic Partners With Eli Lilly Over Potential New Treatment To Combine BrainTransporter Technology with Lilly's Undisclosed Drug Candidate In Neurodegeneration; BioArctic Eligible To Receive $30M Upfront Payment | WAPE

BioArctic Partners With Eli Lilly Over Potential New Treatment To Combine BrainTransporter Technology with Lilly's Undisclosed Drug Candidate In Neurodegeneration; BioArctic Eligible To Receive $30M Upfront Payment

Article summary

Related companies

Comments —